About Retain Biotech

Retain Biotech is dedicated to building a health care map and providing personalized preventive medicine health management services.

Retain Biotech is the first joint venture of National Taiwan University and YongLin Healthcare Foundation, incorporating tripartite resources from industry, academia and research sectors. We integrate the research strength from National Taiwan University, years of extensive clinical experience in the field of stem cell therapy from Tai Chen Cell Therapy Center and vast resources put into the fields of preventive medicine and cancer therapy by YongLin Healthcare Foundation .

From the perspective of preventive medicine, Retain Biotech achieves personalized healthcare management with the preservation of stem cells or immune cells at the early stage and high-end healthcare management. By integrating big data analysis, the most appropriate disease management will be provided by our service. When disease occur, we can maximize and optimize the application of medical resources.

Our Vision

To be the leading brand of personalized precision medicine in the fight against cancer.

Our Mission

To provide trustworthy health management services.

Core Values

Integrity and honesty, Entrustment with Commitment, Excellence and Innovation.

Concept Video

Milestone

2023

April

Get the approval from the Ministry of Economic Affairs, R.O.C., to be listed as the Biotech and Pharmaceutical Companies

2022

December

BioNTech Announces Plans for a Clinical Trial Hub in Taiwan for mRNA-based Cancer Immunotherapies as Part of Asia-Pacific Expansion

November

Retain Biotech Signed a MOU with BioNTech

Retain Biotech Corporation Signed a Memorandum of Understanding with BioNTech to Support Clinical Trials in the Field of Oncology in East Asia

May

Ethical Management Declaration

We, Company uphold the principles of fairness, honesty, trustworthiness and transparency in all business activities and which is regarded as the most important core value for sustainable business development. In order to implement ethical management and prevent unethical issues accordingly, we have formally formulated the “Procedures for Ethical Management and Guidelines for Conduct” (the Procedures), which has specifically regulated the matters for all staff attention and compliance when conducting business.

2021

May

Successfully developed automated CAR-T manufacturing process

2020

September

Successfully developed CAR-T manufacturing process

2017

September

ISO:9001 Certified

August

Grand Opening

Peripheral Blood Immune Cell storage service

Peripheral Blood Stem Cell storage service

Offically Established

2016

November

Sign up contract with NTU

” peripheral blood stem cell and immune cell collection, freezing, and storage ” technique exclusively authorized.

March

Business registration

The Founding Years

2015

December

National Taiwan University Center of Industry-Academia Collaboration Council authorized the new cooperation (i.e. Retain Biotech Corporation) to be established.

The fist joint venture of NTU, Foxconn and YongLin Healthcare Foundation